The State Institute for Drug Control has issued a notice about the withdrawal of a well-known drug for high blood pressure, for treatment after a heart attack and, at the same time, intended for patients with type 2 diabetes mellitus (diabetes).
The reason for this step is said to be a significant deficiency in the quality of the medicine in question.
A few hours ago a public announcement was published about the withdrawal of a preparation containing sartans. This is the drug.
,, SÚKL informs about the withdrawal of the preparation Irbesartan Actavis 300 mg, tbl flm 28 × 300 mg with batch number 015418 from the market, “it says on the website.
For patients taking the mentioned drug there is, however, no acute danger, and a sudden discontinuation of treatment is definitely not recommended. But it is necessary that they visit their attending physician within one month, who will then prescribe another suitable treatment from the available alternatives.
